Clinical trial costs

Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)

Average per-patient trial costs across all therapeutic areas:

Phase I: $21,883

Phase II: $36,070

Phase IIIa: $47,523

Phase IIIb: $47,095

Phase IV: $17,042

Average cost per patient for a cardiovascular trial:

Phase II: $33,700

Phase IIIa: $21,750

Phase IIIb: $6,830

In oncology, the average per patient trial cost:

Phase II: $73,303

Phase IIIa: $57,207

Phase IIIb: $65,900

For central nervous system disorders:

Phase II: $28,197

Phase IIIa: $33,768

Phase IIIb: $41,824

For diabetes:

Phase II: $ 8,854

Phase IIIa: $12,667

Phase IIIb: $10,700

Anyone have any thoughts or data as to how this compares to cell therapy trials?

--Lee

*survey conducted by Cutting Edge Information.

Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations

in collaboration with:

In an effort to showcase the latest technologies driving the production of cell therapies, the Cell Therapy Group and Informa Life Sciences are proud to announce the introduction of the "Technology Showcase" session and award to be held in conjunction with Informa's Cell Therapy Manufacturing conference to be held 30 November to 1 December 2011 in Brussels Belgium.

Having held the same conference last year in London, Informa is committed to building on the success of last year's event by continuing to create a meaningful European forum for the issues related to the clinical and particularly commercial-scale production of cell-based therapies.

The Technology Showcase session, taking place on the main agenda, will feature 6 x 10 minute presentations from innovative companies developing cutting-edge technologies in the field of cell therapy manufacturing, and is particularly relevant to SME and academic groups with limited marketing resources.

All presentations will be reviewed by the Scientific Advisory Board with the winner announced at the end of the session. Exposure on BioProcess International's website is also included.

Technologies we'd like to promote include:

• Manufacturing systems including bioreactor technologies
• Cell harvest/collection technologies
• Cell storage/logistics technologies
• Clinical cell delivery and/or other point-of-care technologies
• Automation technologies
• Cell separation system
• Cell process devices
• Innovative reagents, scaffolds, matrices, and other “ancillary” tools
• Technologies to close currently open systems
• Suspension-based production systems
• Disposable technologies

How to apply:

To apply to present companies must submit an abstract (<300 words) to daniel.barry@informa.com and lbuckler@celltherapygroup.com outlining the product or service to be presented and why it is a critical technology related to cell therapy manufacturing.

The deadline for applications is SEPTEMBER 15 2011 - Priority given to early submissions

The cost of taking part in the Technology Showcase is £2,700 which includes the following benefits:

• 1 x 2-day conference pass (normal price £1,599)
• 10-minute podium presentation within main conference room
• 1 poster display in the Exhibition Hall
• Marketing - company logo displayed on website and event guide
• Exposure in BPI Magazine

Terms and conditions:

To be eligible the product or service to be presented must be:

• On the market for no less than 2 years or expected to be on the market no later than Q4 2012
• Appropriate for, applicable to, and compliant with clinical-grade manufacturing requirements (technologies only available for research use will not be considered)

Plus...

• The company must have no more than 15 employees
• The company has been running for no more than 5 years, and
• The company generates annual revenue of no more than $5m

For further information please contact: daniel.barry@informa.com or lbuckler@celltherapygroup.com